Overview
Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer
Status:
Completed
Completed
Trial end date:
2007-04-01
2007-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Kentuckiana Cancer InstituteTreatments:
Gemcitabine
Criteria
Inclusion Criteria:- newly diagnosed IIIB and IV NSCLC who have failed one prior line of chemo
- Karnofsky score 60% or greater
- patients who will be treated with Gemcitabine